Analyst Jason McCarthy from Maxim Group maintained a Buy rating on OS Therapies Incorporated and keeping the price target at $6.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Jason McCarthy has given his Buy rating due to a combination of factors that highlight the potential of OS Therapies Incorporated. The company is advancing its lead asset, OST-HER2, which is a promising cancer immunotherapy targeting HER2-expressing cancer cells. This therapy has shown positive results in clinical trials, particularly in recurrent osteosarcoma, and holds several FDA designations that could expedite its approval process.
Additionally, OS Therapies has scheduled important regulatory meetings with both the FDA and the European Medicines Agency, which could pave the way for accelerated approval and market entry. The company’s strategic moves in securing a Scientific Advice Meeting and pursuing conditional marketing authorization in the UK further bolster its growth prospects. The potential for a priority review voucher, if OST-HER2 is approved, represents a significant opportunity for non-dilutive capital, enhancing the company’s financial outlook. These factors collectively support the Buy rating, with a price target of $6.00.
In another report released today, Lake Street also maintained a Buy rating on the stock with a $19.00 price target.
Based on the recent corporate insider activity of 7 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of OSTX in relation to earlier this year.